Abstract:
At present, statins are included in the first line of dyslipidemia therapy. Fibrates also take a certain
place in the treatment of dyslipidemia. Given the above, it is advisable to study the pharmacoeconomic
characteristics of fibrates presented on the pharmaceutical market of Ukraine.
The work aimed to explore the range, socio-economic accessibility, and consumption of fibrates in
the pharmaceutical market of Ukraine during 2017-2020.
Materials and methods. A retrospective analysis of the range, prices, accessibility, and consumption
of fibrates in Ukraine was conducted using the data of the analytical system "PharmXplorer" by
information retrieval company "Morion" and the Compendium system. The assessment of economic
accessibility was carried out on the indicator of solvency adequacy (Ca.s.), consumption volumes - on
the indicator of DDDs (number of defined daily doses (DDD)), and the number of sold packages during
2017-2020.
Results and discussion. During 2017-2020, only 3 trade names (TN) of foreign-produced fenofibrate
were registered on the pharmaceutical market of Ukraine, the prices of which did not fluctuate
significantly. The fenofibrate drug - Lipofen SR (Nobel, Turkey) capsules 250 mg No. 30 in a blister is
highly available to Ukrainian consumers (Ca.s. less than 5.0%), and the drug Tricor® 145 mg (Abbott
Products GmbH, Germany) film-coated tablets 145 mg No. 20 and No. 30 in a blister (Ca.s. more than
5.0%) - moderately available. The dynamics of growth in sales of fenofibrate packaging in 2019-2020
compared to 2017-2018 has been established due to growth in sales of the drug "Tricor®" (film-coated
tablets 145 mg No. 20 in a blister). The dynamics of increasing the consumption of fibrates in terms o f
DDDs, which generally corresponds to the dynamics of sales in the number of packages have been
identified, but consumption volumes are insignificant.
Conclusions. Consumption of fibrates in the Ukrainian pharmaceutical market is insignificant as
determined by their clinical efficacy and place in antihyperlipidemic CVD therapy, where statins
predominate today.
